Revvity, Inc. has unveiled the IDS i20™, a fully automated analytical platform developed by EUROIMMUN, designed to enhance chemiluminescence immunoassay (ChLIA) processing. This CE marked and FDA listed instrument enables contract laboratories to efficiently manage multiple specialty tests on a single device.
Benefits for Contract Testing Labs:
- Multi-Specialty Testing: Handles 20 analytes across endocrinology, allergy, autoimmune, infectious diseases, Alzheimer’s, and therapeutic drug monitoring.
- High Throughput: Capable of processing up to 140 tests per hour, meeting high-demand testing requirements.
- Continuous Operation: Features continuous loading and reagent cooling for uninterrupted workflows.
- Advanced Software: Offers scalable and adaptable software with a user-friendly interface, ensuring ease of use.
- Regulatory Compliance: CE marked and FDA listed, facilitating adherence to international standards.
The IDS i20™ platform provides contract laboratories with a robust solution for automating immunoassay specialty testing, enhancing efficiency, and ensuring compliance with regulatory standards.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: “Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing.”
